Axsome Therapeutics (AXSM) Total Liabilities (2015 - 2026)

Axsome Therapeutics has disclosed Total Liabilities across 12 years of filings, most recently posting $659.0 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $659.0 million, up 21.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $659.0 million (up 21.26% YoY), and the FY2025 annual result was $601.5 million, up 17.6% from the prior year.
• Total Liabilities came in at $659.0 million for Q1 2026 at Axsome Therapeutics, up from $601.5 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $659.0 million in Q1 2026 to a low of $73.9 million in Q1 2022.
• The 5-year median for Total Liabilities is $401.7 million (2024), against an average of $398.5 million.
• Across the five-year window, Total Liabilities advanced 4.6% in 2022 and soared 275.52% in 2023, its largest moves.
• Axsome Therapeutics' Total Liabilities stood at $221.9 million in 2022, then jumped by 79.01% to $397.3 million in 2023, then advanced by 28.75% to $511.5 million in 2024, then advanced by 17.6% to $601.5 million in 2025, then gained by 9.56% to $659.0 million in 2026.
• The last three Total Liabilities figures came in at $659.0 million (Q1 2026), $601.5 million (Q4 2025), and $595.5 million (Q3 2025), per Business Quant data.